open access
New synthesis route of active substance d,l-HMPAO for preparation Technetium Tc99m Exametazime
Affiliations- National Centre for Nuclear Research, Radioisotope Centre POLATOM, ul. Andrzeja Sołtana 7, 05-400 Otwock -Świerk, Poland
open access
Abstract
BACKGROUND: Technetium Tc99m Exametazime (99mTc-HMPAO) is currently used as a radiopharmaceutical for determining regional cerebral blood flow and for the labelling of autologous leucocytes for infection and inflammation imaging. The HMPAO ligand exists in two diastereomeric forms: d,l and meso. Usually, the substance is obtained in low chemical yield in a time consuming procedure. Furthermore, the final product still contains some amounts of the meso-form. The aim of this study was to develop the efficient, reliable and fast method for isolation of the d,l-HMPAO, which would provide the ligand with high purity and free from the meso-diastereomer.
MATERIAL AND METHODS: The mixture of the meso- and d,l-HMPAO was synthesized in two-steps by condensation of propanediamine with keto-oxime and the reduction of the obtained bisimine. The d- and l-enantiomers were separated individually directly from this mixture by repeated crystallizations from ethanol as their tartrate salts and pooled together in equal proportions. That substance was characterized for its identity and isomeric purity using IR, HPLC and GC methods. The meso-free d,l-HMPAO was used for the preparation of the radiopharmaceutical freeze-dried kit for technetium-99m radiolabelling. Quality assessment of obtained 99mTc-d,l-HMPAO complex was performed according to the current Ph.Eur. monograph 1925 and USP monograph — Technetium Tc99m Exametazime Injection. To verify its biological activity, the kit-prepared 99mTc-d,l-HMPAO has been used for the white blood cell (WBC) labelling.
RESULTS: According to the proposed synthesis route the d,l-HMPAO was obtained with around 18–20% yield in the total time of 10 days. The ligand identity was confirmed and the HPLC analysis revealed more than 99% chemical purity. The undesired meso-form was not detected. Freeze dried kit formulation for 99mTc-labelling of d,l-HMPAO has been established and four batches of kits were manufactured. The radiochemical purity of 99mTc-d,l-HMPAO complex was high (> 95% of lipophilic technetium-99m exametazime). Brain uptake in rats reached 2.1 ± 0.3%. The in vitro labelling of WBC resulted in 68.3 ± 6.6% yield.
CONCLUSION: A new synthesis method of d,l-HMPAO, drug substance for technetium-99m exametazime preparation has been developed.
Abstract
BACKGROUND: Technetium Tc99m Exametazime (99mTc-HMPAO) is currently used as a radiopharmaceutical for determining regional cerebral blood flow and for the labelling of autologous leucocytes for infection and inflammation imaging. The HMPAO ligand exists in two diastereomeric forms: d,l and meso. Usually, the substance is obtained in low chemical yield in a time consuming procedure. Furthermore, the final product still contains some amounts of the meso-form. The aim of this study was to develop the efficient, reliable and fast method for isolation of the d,l-HMPAO, which would provide the ligand with high purity and free from the meso-diastereomer.
MATERIAL AND METHODS: The mixture of the meso- and d,l-HMPAO was synthesized in two-steps by condensation of propanediamine with keto-oxime and the reduction of the obtained bisimine. The d- and l-enantiomers were separated individually directly from this mixture by repeated crystallizations from ethanol as their tartrate salts and pooled together in equal proportions. That substance was characterized for its identity and isomeric purity using IR, HPLC and GC methods. The meso-free d,l-HMPAO was used for the preparation of the radiopharmaceutical freeze-dried kit for technetium-99m radiolabelling. Quality assessment of obtained 99mTc-d,l-HMPAO complex was performed according to the current Ph.Eur. monograph 1925 and USP monograph — Technetium Tc99m Exametazime Injection. To verify its biological activity, the kit-prepared 99mTc-d,l-HMPAO has been used for the white blood cell (WBC) labelling.
RESULTS: According to the proposed synthesis route the d,l-HMPAO was obtained with around 18–20% yield in the total time of 10 days. The ligand identity was confirmed and the HPLC analysis revealed more than 99% chemical purity. The undesired meso-form was not detected. Freeze dried kit formulation for 99mTc-labelling of d,l-HMPAO has been established and four batches of kits were manufactured. The radiochemical purity of 99mTc-d,l-HMPAO complex was high (> 95% of lipophilic technetium-99m exametazime). Brain uptake in rats reached 2.1 ± 0.3%. The in vitro labelling of WBC resulted in 68.3 ± 6.6% yield.
CONCLUSION: A new synthesis method of d,l-HMPAO, drug substance for technetium-99m exametazime preparation has been developed.
Keywords
99mTc-d,l-HMPAO, chemical synthesis, 99mTc-exametazime, brain SPECT, infection imaging
About this articleTitle
New synthesis route of active substance d,l-HMPAO for preparation Technetium Tc99m Exametazime
Journal
Issue
Article type
Research paper
Pages
88-94
Published online
2017-05-25
Page views
1958
Article views/downloads
1356
DOI
Pubmed
Bibliographic record
Nucl. Med. Rev 2017;20(2):88-94.
Keywords
99mTc-d
l-HMPAO
chemical synthesis
99mTc-exametazime
brain SPECT
infection imaging
Authors
Justyna Pijarowska-Kruszyna
Urszula Karczmarczyk
Antoni Włodzimierz Jaroń
Ewa Laszuk
Marcin Radzik
Piotr Garnuszek
Renata Mikołajczak
References (18)- Nowotnik DP, Canning LR, Cumming SA, et al. Development of a 99Tcm-labelled radiopharmaceutical for cerebral blood flow imaging. Nucl Med Commun. 1985; 6(9): 499–506.
- Holmes RA, Chaplin SB, Royston KG, et al. Cerebral uptake and retention of 99Tcm-hexamethylpropyleneamine oxime (99Tcm-HM-PAO). Nucl Med Commun. 1985; 6(8): 443–447.
- Neirinckx RD, Canning LR, Piper IM, et al. Technetium-99m d,l-HM-PAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J Nucl Med. 1987; 28(2): 191–202.
- Neirinckx RD, Harrison RC, Forster AM, et al. et al.. A model for the in vivo behavior of Tc-99m d, l-HMPAO on man. J Nucl Med. 1987; 28: 559.
- Kapucu OL, Nobili F, Varrone A, et al. EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2. Eur J Nucl Med Mol Imaging. 2009; 36(12): 2093–2102.
- de Vries EFJ, Roca M, Jamar F, et al. Guidelines for the labelling of leucocytes with (99m)Tc-HMPAO. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2010; 37(4): 842–848.
- Canning LR, Nowotnik DP, Neirinckx RD, et al. Complexes of technetium-99m with propylene amine oximes. European Patent. ; 0194843.
- Sharp PF, Smith FW, Gemmell HG, et al. Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies. J Nucl Med. 1986; 27(2): 171–177.
- Hoffman TJ, Corlija M, Reitz R, et al. Biological evaluation of the Tc-99m complexes of the D and L isomers of HMPAO. J Nucl Med. 1992; 33: 1032.
- Kang CS, Chang YS, Jeong JM, et al. Synthesis of d- and l-form of 99mTc-HMPAO, and comparison of brain uptake. Korean J Nucl Med. 2001; 35(1): 69–74.
- European Pharmacopoeia, monograph 1925 Technetium (99mTc) exametazime injection.
- The U.S. Pharmacopeia (USP) monograph: Technetium Tc 99m Exametazime Injection.
- Banerjee S, Samuel G, Kothari K, et al. On the synthesis, isolation, and radiochemical studies for the preparation of in-house kits for 99mTc-meso- and d,l-HMPAO: a few additional observations. Nucl Med Biol. 1999; 26(3): 327–338.
- IAEA Technical Reports Series no. 466. Technetium-99m Radiopharmaceuticals: Manufacturing of Kits. , Vienna 2008: 140–143.
- Nowotnik DP, Nanjappan P, Zeng W, et al. Separation of the Stereoisomers of Hexamethyl-Propyleneamine Oxime (HM-PAO) by High-Performance Liquid Chromatography. Journal of Liquid Chromatography. 1995; 18(4): 673–687.
- European Pharmacopeia, monograph 5.12. Reference Standards.
- SmPC GE Healthcare, Ceretec. www3.gehealthcare.com.
- Seguí GV, Engroñat RM, Muñoz AF, et al. [Stabilization of 99m Tc-HMPAO with methylene blue: its use in leukocyte labelling)]. Rev Esp Med Nucl. 1998; 17(4): 261–264.
